Cancer risk among elderly persons with end-stage renal disease: A population-based case-control study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Shebl, Fatma M ^a,c   Warren, Joan L ^a   Eggers, Paul W ^b   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Cancer; Dialysis; End Stage Renal Disease; ESKD; ESRD

Indexed keywords

AGED; ARTICLE; BILIARY TRACT CANCER; CANCER RISK; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; KIDNEY CANCER; KIDNEY FAILURE; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; RISK ASSESSMENT; SMALL INTESTINE CANCER; STATISTICAL ANALYSIS; STOMACH CANCER; UTERINE CERVIX CANCER;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASMS; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 84864125913     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-65     Document Type: Article

References (49)

1. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Betheda, MD 2011
2. The immune system in end-stage renal disease. Descamps-Latscha B, Curr Opin Nephrol Hypertens 1993 2 6 883 891 10.1097/00041552-199311000-00005 7922228
3. Aspects of immune dysfunction in end-stage renal disease. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B, Clin J Am Soc Nephrol 2008 3 5 1526 1533 10.2215/CJN.00950208 18701615
4. Increased incidence of malignancy during chronic renal failure. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS, Lancet 1975 1 7912 883 886 47534
5. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, et al. Lancet 1999 354 9173 93 99 10.1016/S0140-6736(99)06154-1 10408483 (Pubitemid 29313142)
6. Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A, Nephron 1991 59 4 611 617 10.1159/000186652 1766501
7. Increased incidence of neoplasia in chronic renal failure (20-year experience). Cengiz K, Int Urol Nephrol 2002 33 1 121 126 10.1023/A: 1014489911153 12090317
8. Are chronic dialysis patients at increased risk for cancer? Mandayam S, Shahinian VB, J Nephrol 2008 21 2 166 174 18446710
9. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P, J Am Soc Nephrol 2003 14 1 197 207 10.1097/01.ASN.0000039608.81046.81 12506152 (Pubitemid 36026310)
10. The pattern of excess cancer in dialysis and transplantation. Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, McDonald SP, Grulich AE, McCredie MR, Nephrol Dial Transplant 2009 24 10 3225 3231 10.1093/ndt/gfp331 19589786
11. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF, Med Care 2002 40 8 3 18
12. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL, Am J Epidemiol 2011 174 7 860 870 10.1093/aje/kwr146 21821540
13. Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. Taneja S, Mandayam S, Kayani ZZ, Kuo YF, Shahinian VB, Clin J Am Soc Nephrol 2007 2 5 1008 1013 10.2215/CJN.00310107 17702737
14. Cancer incidence before and after kidney transplantation. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE, JAMA 2006 296 23 2823 2831 10.1001/jama.296.23.2823 17179459 (Pubitemid 44969182)
15. Cancer risk in patients on dialysis and after renal transplantation. Birkeland SA, Lokkegaard H, Storm HH, Lancet 2000 355 9218 1886 1887 10.1016/S0140-6736(00)02298-4 10866449 (Pubitemid 30311885)
16. Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Ishikawa I, Saito Y, Shikura N, Kitada H, Shinoda A, Suzuki S, Am J Kidney Dis 1990 16 5 452 458 2239936
17. Vitamin D insufficiency and deficiency in chronic kidney disease. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ, A single center observational study. Am J Nephrol 2004 24 5 503 510
18. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, Cohen HJ, Am J Physiol 1994 266 2 Pt 1 367 375 8141250
19. Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. Bonomini M, Forster S, De Risio F, Rychly J, Nebe B, Manfrini V, Klinkmann H, Albertazzi A, Nephrol Dial Transplant 1995 10 9 1654 1661 8559485
20. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Yoshimura S, Suemizu H, Nomoto Y, Sakai H, Katsuoka Y, Kawamura N, Moriuchi T, Nephron 1996 73 2 207 211 8773346 (Pubitemid 26159338)
21. Selenium, folate, and colon cancer. Connelly-Frost A, Poole C, Satia JA, Kupper LL, Millikan RC, Sandler RS, Nutr Cancer 2009 61 2 165 178 10.1080/01635580802404188 19235033
22. Reanalysis of epidemiological data for selenium anti-cancer activity. Lange JH, Toxicol Ind Health 1991 7 4 319 325 1780874
23. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL, J Natl Cancer Inst 2007 99 14 1120 1129 10.1093/jnci/djm038 17623801 (Pubitemid 47241396)
24. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench-a critical review. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L, Biochim Biophys Acta 2010 1806 1 82 95 20406667
25. HBV infection in patients with end-stage renal disease. Fabrizi F, Bunnapradist S, Martin P, Semin Liver Dis 2004 24 Suppl 1 63 70 15192803 (Pubitemid 38738360)
26. Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. de Medina M, Ashby M, Schluter V, Hill M, Leclerq B, Pennell JP, Jeffers LJ, Reddy KR, Schiff ER, Hess G, et al. Am J Kidney Dis 1998 31 2 224 226 10.1053/ajkd.1998.v31.pm9469491 9469491 (Pubitemid 28106412)
27. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE, Gut 2002 51 3 429 433 10.1136/gut.51.3.429 12171969
28. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. Fairley CK, Chen S, Tabrizi SN, McNeil J, Becker G, Walker R, Atkins RC, Thomson N, Allan P, Woodburn C, et al. Nephrol Dial Transplant 1994 9 4 416 420 8084456 (Pubitemid 24136276)
29. Transitional cell tumors of the renal pelvis in analgesic abusers. Bengtsson U, Angervall L, Ekman H, Lehmann L, Scand J Urol Nephrol 1968 2 3 145 150 10.3109/00365596809135358 5730975
30. Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin-containing analgesics. Johansson S, Angervall L, Bengtsson U, Wahlqvist L, Cancer 1974 33 3 743 753 10.1002/1097-0142(197403)33:3<743::AID- CNCR2820330321>3.0.CO;2-M 4815577
31. Renal cystic diseases and renal neoplasms: a mini-review. Bonsib SM, Clin J Am Soc Nephrol 2009 4 12 1998 2007 10.2215/CJN.02020309 19875768
32. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, Durrbach A, Droupy S, Benoit G, Urology 2009 74 3 631 634 10.1016/j.urology.2009.02.078 19616833
33. Polycystic kidney disease: neoplasia in disguise. Grantham JJ, Am J Kidney Dis 1990 15 2 110 116 2405652
34. Acquired cystic kidney disease and arterial hypertension in hemodialysis patients. Ekart R, Hojs R, Wien Klin Wochenschr 2006 118 Suppl 2 17 22 16817038 (Pubitemid 43989528)
35. Acquired cysts and neoplasms of the kidneys in renal allograft recipients. Ishikawa I, Contrib Nephrol 1992 100 254 268 1458906
36. Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection, and management. Levine E, Urol Radiol 1992 13 4 203 210 1598743
37. Renal cancer complicating acquired cystic kidney disease. Marple JT, MacDougall M, Chonko AM, J Am Soc Nephrol 1994 4 12 1951 1956 7919148
38. Twenty-year follow-up of acquired renal cystic disease. Ishikawa I, Saito Y, Asaka M, Tomosugi N, Yuri T, Watanabe M, Honda R, Clin Nephrol 2003 59 3 153 159 12653256 (Pubitemid 36348251)
39. Renal cell carcinoma in acquired cystic kidney disease. Fleming S, Histopathology 2010 56 3 395 400 10.1111/j.1365-2559.2010.03492.x 20459539
40. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE, Transplantation 1998 66 12 1669 1672 10.1097/00007890-199812270-00017 9884257 (Pubitemid 29034989)
41. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20year follow up study. Silman AJ, Petrie J, Hazleman B, Evans SJ, Ann Rheum Dis 1988 47 12 988 992 10.1136/ard.47.12.988 3207388 (Pubitemid 19005407)
42. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, et al. J Natl Cancer Inst 1995 87 7 524 530 10.1093/jnci/87.7.524 7707439
43. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H, J Natl Cancer Inst 2009 101 6 374 383 10.1093/jnci/djp001 19276453
44. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A, Nephrol Dial Transplant 2009 24 4 1238 1241 19028756
45. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Moyer VA, Ann Intern Med 2012 157 2 120 134 22801674
46. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Betheda, MD 2007
47. Cost-effectiveness of cancer screening in end-stage renal disease. Chertow GM, Paltiel AD, Owen WF, Lazarus JM, Arch Intern Med 1996 156 12 1345 1350 10.1001/archinte.1996.00440110117016 8651845 (Pubitemid 26196895)
48. Cancer screening and detection in patients with end-stage renal disease. Gornik HL, Lazarus JM, Chertow GM, The International journal of artificial organs 1998 21 9 495 500 9828052 (Pubitemid 28494314)
49. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Holley JL, Clin J Am Soc Nephrol 2007 2 3 604 610 10.2215/CJN.03931106 17699470